TY - JOUR
KW - Gram negative bacteria
KW - Gram positive bacteria
KW - cell-free system
KW - fungi
KW - human in vivo production
KW - insect cells
KW - mammalian cells
KW - microalgae
AU - Esther Veronika Wenzel
AU - Laila Al-Halabi-Frenzel
AU - Seyhan Demiral
AU - André Frenzel
AU - Dianne Celine Gnann
AU - Martha Charlotte-Elisabeth Keitel
AU - Nina Lehmler
AU - Tarushyam Mukherjee
AU - Justus Rauls
AU - Thomas Schirrmann
AU - Piotr Grzegorz Stańczyk
AU - Stephan Steinke
AU - Jan Terbrack
AU - Sofie Westerhoff
AU - Stefan Dübel
AU - Maren Schubert
AU - Michael Hust
AU - Federico Bertoglio
AB - Over the past three decades, the emergence of recombinant antibodies has positioned them as the fastest-growing class of therapeutic proteins and as well as crucial reagents for both diagnostics and specific research applications. The industrial production of most therapeutic antibodies currently relies on mammalian cell lines, primarily Chinese Hamster Ovary (CHO) cells, which remain the gold standard in biopharmaceutical manufacturing due to their exceptionally high production yields, robustness, regulatory acceptance, and consistent product quality. Nevertheless, new approaches using specifically adapted expression systems are emerging. These new host organisms enable the production of antibodies with posttranslational modifications that closely resemble those found in the human system, without the need for animal-derived source materials. For diagnostic and research purposes, a broad range of production systems has been developed. These include Gram-negative and Gram-positive bacteria, yeasts, filamentous fungi, insect cell lines, and transgenic plants. Additionally, smaller single domain antibodies and bispecific fragments that do not require glycosylation can be successfully produced in bacteria for therapeutic applications. Some of these molecules have already been approved by regulatory authorities in the European Union and the United States, and several more are currently in clinical trials. This review therefore focuses on the broad and evolving landscape of recombinant antibody production systems and their applicability across various fields.
BT - Frontiers in Bioengineering and Biotechnology
DA - 2026-05-20
DO - 10.3389/fbioe.2026.1765764
LA - English
N2 - Over the past three decades, the emergence of recombinant antibodies has positioned them as the fastest-growing class of therapeutic proteins and as well as crucial reagents for both diagnostics and specific research applications. The industrial production of most therapeutic antibodies currently relies on mammalian cell lines, primarily Chinese Hamster Ovary (CHO) cells, which remain the gold standard in biopharmaceutical manufacturing due to their exceptionally high production yields, robustness, regulatory acceptance, and consistent product quality. Nevertheless, new approaches using specifically adapted expression systems are emerging. These new host organisms enable the production of antibodies with posttranslational modifications that closely resemble those found in the human system, without the need for animal-derived source materials. For diagnostic and research purposes, a broad range of production systems has been developed. These include Gram-negative and Gram-positive bacteria, yeasts, filamentous fungi, insect cell lines, and transgenic plants. Additionally, smaller single domain antibodies and bispecific fragments that do not require glycosylation can be successfully produced in bacteria for therapeutic applications. Some of these molecules have already been approved by regulatory authorities in the European Union and the United States, and several more are currently in clinical trials. This review therefore focuses on the broad and evolving landscape of recombinant antibody production systems and their applicability across various fields.
PY - 2026
ST - The landscape of antibody production systems
T2 - Frontiers in Bioengineering and Biotechnology
TI - The landscape of antibody production systems: recombinant expression for research, diagnostics and therapy
UR - https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2026.1765764/full
VL - 14
Y2 - 2026-05-21
SN - 2296-4185
ER -